DX
DXCM
Quarter ended Sep 30, 2025 · FY2025 Q3

DexCom (DXCM) Revenue — Quarter Ended Sep 30, 2025

Revenue increased for the quarter, continuing the positive trend from the prior period and showing higher growth compared to the same period a year ago.

Key takeaway

Quarter ended Sep 30, 2025 · FY2025 Q3

Revenue increased for the quarter, continuing the positive trend from the prior period and showing higher growth compared to the same period a year ago.

Financial snapshot

Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.

Quarter revenue

$1.2B

Revenue reported for this quarter.

Quarter-over-quarter

+4.5%

Change from the immediately preceding quarter.

Year-over-year

+21.6%

Change from the comparable year-ago quarter.

Trailing four quarters

$4.5B

Sum of the latest four reported quarters.

Quarterly revenue trend

The latest four reported quarters with year-over-year comparisons.

Period endedRevenueYear-over-year change
Dec 31, 2024$1.1B+7.6%
Mar 31, 2025$1B+12.5%
Jun 30, 2025$1.2B+15.2%
Sep 30, 2025$1.2B+21.6%

Revenue performance

The reported revenue rose, reflecting continued expansion from the immediately preceding quarter.

Quarterly comparison

Compared to the immediately preceding quarter, revenue improved. Versus the same quarter one year earlier, revenue also increased, with a larger gain than the sequential change.

What to watch

Future revenue performance will depend on the company's ability to scale operations and meet product demand globally.